Fatty acid amide hydrolase in prostate cancer: Association with disease severity and outcome, CB1 receptor expression and regulation by IL-4

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Thors, Lina ^a   Bergh, Anders ^a   Persson, Emma ^a   Hammarsten, Peter ^a   Stattin, Pär ^a   Egevad, Lars ^b   Granfors, Torvald ^c   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; FATTY ACID AMIDASE; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; AMIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY-ACID AMIDE HYDROLASE;

ANIMAL CELL; ARTICLE; BLOOD VESSEL WALL; CANCER CELL CULTURE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EMBEDDING; ENZYME ACTIVITY; EPITHELIUM CELL; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; STROMA; TRANSURETHRAL RESECTION; TUMOR MICROENVIRONMENT; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

AMIDOHYDROLASES; CELL LINE, TUMOR; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-4; MALE; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77957906635     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012275     Document Type: Article

References (66)

1. Pisanti S, Bifulco M (2009) Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 60: 107-116.
2. Freimuth N, Ramer R, Hinz B (2010) Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 332: 336-344.
3. Fowler CJ, Gustafsson SB, Chung SC, Persson E, Jacobsson SO, et al. (2010) Targeting the Endocannabinoid System for the Treatment of Cancer - A Practical View. Curr Top Med Chem 10: 814-827.
4. Galve-Roperh I, Sánchez C, Cortés M, Gómez del Pulgar T, Izquierdo M, et al. (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med 6: 313-319.
5. 9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Letts 458: 400-404.
6. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, et al. (2000) Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141: 118-126.
7. Mimeault M, Pommery N, Wattez N, Bailly C, Hénichart J-P (2003) Antiproliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56: 1-12.
8. Nithipatikom K, Endsley M, Isbell M, Falck J, Iwamoto Y, et al. (2004) 2- Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64: 8826-8830.
9. Sarfaraz S, Afaq F, Adhami V, Mukhtar H (2005) Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65: 1635-1641.
10. Sarfaraz S, Afaq F, Adhami V, Malik A, Mukhtar H (2006) Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell arrest. J Biol Chem 281: 39480-39491.
11. Olea-Herrero N, Vara D, Malagarie-Cazenave S, Díaz-Laviada I (2009) Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)- Methanandamide and JWH-015: involvement of CB2. Br J Cancer 101: 940-950.
12. Endsley M, Thill R, Choudhry I, Williams C, Kajdacsy-Balla A, et al. (2008) Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer 123: 1318-1326.
13. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
14. 1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 45: 174-182.
15. Gleason D, Mellinger G (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64.
16. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P (2002) Prognostic value of the Gleason score in prostate cancer. BJU International 89: 538-542.
17. Harkany T, Härtig W, Berghuis P, Dobszay M, Zilberter Y, et al. (2003) Complementary distribution of type 1 cannabinoid receptors and vesicular glutamate transporter 3 in basal forebrain suggests input-specific retrograde signalling by cholinergic neurons. Eur J Neurosci 18: 1979-1992.
18. Tsou K, Nogueron M, Muthian S, Sañudo-Peña M, Hillard C, et al. (1998) Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunochemistry. Neurosci Letts 254: 137-140.
19. Egertová M, Giang D, Cravatt B, Elphick M (1998) A new perspective on cannabinoid signalling: complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B 265: 2081-2085.
20. Harrington C (1990) Lowry protein assay containing sodium dodecyl sulfate in microtiter plates for protein determinations on fractions from brain tissue. Analyt Biochem 186: 285-287.
21. Boldrup L, Wilson SJ, Barbier AJ, Fowler CJ (2004) A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Methods 60: 171-177.
22. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561-577.
23. Perkins NJ, Schisterman EF (2006) The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 163: 670-675.
24. Akobeng AK (2007) Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr 96: 644-647.
25. Cox DR (1972) Regression models and life-tables. J Roy Stat Soc B 34: 187-220.
26. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, et al. (2001) Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J Immunol 166: 7183-7189.
27. Börner C, Höllt V, Sebald W, Kraus J (2007) Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J Leukoc Biol 81: 336-343.
28. Börner C, Bedini A, Höllt V, Kraus J (2008) Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. Mol Pharmacol 73: 1013-1019.
29. Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, et al. (2004) IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 172: 5467-5477.
30. Wise G, Marella V, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164: 722-725.
31. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M (2005) Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 92: 921-928.
32. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, et al. (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402.
33. Olver S, Apte S, Baz A, Kienzle N (2007) The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth? Tissue Antigens 69: 293-298.
34. Li Z, Jiang J, Wang Z-Q, Zhang J, Xiao M, et al. (2008) Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 68: 8687-8694.
35. Lee S, Pinder E, Chun J, Lou W, Sun M, et al. (2008) Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 68: 85-91.
36. Husain SR, Kawakami K, Kawakami M, Puri RK (2003) Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models. Mol Cancer Ther 2: 245-254.
37. Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikström P, et al. (2010) Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 16: 1245-1255.
38. Wikström P, Marusic J, Stattin P, Bergh A (2009) Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 69: 799-809.
39. Field A (2009) Discovering Statistics Using SPSS. Third Edition 270-271. SAGE Publications Ltd., London. ISBN: 9781847879073.
40. Okada H, Tsubura A, Okamura A, Senzaki H, Naka Y, et al. (1992) Keratin profiles in normal/hyperplastic prostates and prostate carcinoma. Virchows Arch A Pathol Anat Histopathol 421: 157-161.
41. Michalski C, Oti F, Erkan M, Sauliunaite D, Bergmann F, et al. (2008) Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 122: 742-750.
42. Goparaju S, Ueda N, Yamaguchi H, Yamamoto S (1998) Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Letts 422: 69-73.
43. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio M, et al. (2003) Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677-687.
44. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, et al. (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606-1608.
45. Jhaveri M, Richardson D, Kendall D, Barrett D, Chapman V (2006) Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26: 13318-13327.
46. Endsley M, Aggarwal N, Isbell M, Wheelock C, Hammock B, et al. (2007) Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer 121: 984-991.
47. Fowler CJ, Ghafouri N (2008) Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? Pharm Res 58: 72-76.
48. Wang D, Wang H, Ning W, Backlund M, Dey S, et al. (2008) Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68: 6468-6476.
49. Xu X, Liu Y, Huang S, Liu G, Xie C, et al. (2006) Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Gen Cytogen 171: 31-38.
50. Sánchez M, Sánchez A, Collado B, Malagerie-Cazenave S, Olea N, et al. (2005) Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur J Pharmacol 515: 20-27.
51. Czifra G, Varga A, Nyeste K, Marincsák R, Tóth B, et al. (2009) Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol 135: 507-514.
52. Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agrò A (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275: 31938-31945.
53. Olea-Herrero N, Vara D, Malagarie-Cazenave S, Díaz-Laviada I (2009) Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)- Methanandamide and JWH-015: involvement of CB2. Br J Cancer 101: 940-950.
54. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, et al. (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140: 49-61.
55. 2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS ONE 5: e8702.
56. Gifford A, Bruneus M, Gatley S, Lan R, Makriyannis A, et al. (1999) Large receptor reserve for canabinoid actions in the central nervous system. J Pharmacol Exp Ther 288: 478-483.
57. Mimeault M, Batra SK (2006) Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27: 1-22.
58. Hart S, Fischer O, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor a-converting enzyme (TACE/ADAM17)- mediated transactivation of the epidermal growth factor. Cancer Res 64: 1943-1950.
59. Lorente M, Carracedo A, Torres S, Natali F, Egia A, et al. (2009) Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia 57: 1374-1385.
60. Hoehe MR, Caenazzo L, Martinez MM, Hsieh WT, Modi WS, et al. (1991) Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol 3: 880-885.
61. Wan M, Cravatt B, Ring H, Zhang X, Francke U (1998) Conserved chromosomal location and genomic structure of human and mouse fatty-acid amide hydrolase genes and evaluation of clasper as a candidate neurological mutation. Genomics 54: 408-414.
62. McPartland J, Norris R, Kilpatrick C (2007) Coevolution between cannabinoid receptors and endocannabinoid ligands. Gene 397: 126-135.
63. Chung L, Baseman A, Assikis V, Zhau H (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20.
64. Waleh N, Cravatt B, Apte-Deshpande A, Terao A, Kilduff T (2002) Transcriptional regulation of the mouse fatty acid amide hydrolase gene. Gene 291: 203-210.
65. Maccarrone M, Di Rienzo M, Finazzi-Agrò A, Rossi A (2003) Leptin activates the anandamide hydrolase promoter in hyman T lymphocytes through STAT3. J Biol Chem 278: 13318-13324.
66. Rossi G, Gasperi V, Paro R, Barsacchi D, Cecconi S, et al. (2007) Folliclestimulating hormone activates fatty acid amide hydrolase by protein kinase A and aromatase-dependent pathways in mouse primary sertoli cells. Endocrinology 148: 1431-1439.